|会社名||Antares Pharma Inc. （アンタレス・ファ―マ）|
|分野（sector）||Health Care ヘルスケア|
|業種||医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care）|
|概要||事業概要 アンタレス・ファーマ(Antares Pharma Inc.)は自己投与される非経口医薬品および技術の開発・商業化に従事する専門医薬品会社である。同社は患者が薬物を自己注射することを可能にするニードル有り・無しの圧力補助式注射器を開発・製造する。同社の皮下注射技術プラットフォームは、VIBEX使い捨て圧力支援自動インジェクタ、Vision再使用可能な無針注射器、及び使い捨ての多目的ペンインジェクタを含む。同社は薬物送達事業セグメントを通じて運営する。薬物送達事業は自己投与される非経口医薬品および技術を含む。同社は単回用量の使い捨て自動注射器であるOTREXUP（メトトレキセート）注射剤を開発した。 アンタレス・ファ―マは、米国の医薬品メ―カ―。無針・微小針の注射システムや経皮ジェルなどの薬品送達システムを開発、製造、販売する。主な商品は、関節リウマチに対するメトトレキサ―トの皮下注製剤｢OTREXUP｣、自己注製剤｢Medi-Jet｣、使い捨て可能な自動注入器｢Vibex｣など。本社は、ニュ―ジャ―ジ―州イウィング。 Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.|
|本社所在地||100 Princeton South Suite 300 Ewing NJ 08628 USA|
|代表者氏名||Leonard S. Jacob レオナルドS.ジェイコブ|
|代表者役職名||Independent Chairman of the Board|
|市場名||NASDAQ Small Cap|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Antares Pharma Inc revenues increased 6% to $26.9M. Net loss increased 41% to $10.7M. Revenues reflect Europe segment increase of 42% to $3.2M United States of America segment increase of 3% to $23.4M. Higher net loss reflects Research and development increase of 12% to $7M (expense) Selling general and administrative increase of 3% to $15.3M (expense).|
Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference 2022/02/28 13:30:00 GlobeNewswire
EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42 nd Annual Healthcare Conference being held on March 7-9, 2022.
Antares Pharma Inc. (NASDAQ: ATRS) Is Up 4.18% In A Month. Could There Be Any Hope That It Will Rise Soon? 2022/02/19 15:30:00 Marketing Sentinel
During the last session, Antares Pharma Inc. (NASDAQ:ATRS)s traded shares were 0.46 million, with the beta value of the company hitting 1.49. At the end of the trading day, the stocks price was $3.49, reflecting an intraday loss of -2.51% or -$0.09. The 52-week high for the ATRS share is $5.07, that puts it down Antares Pharma Inc. (NASDAQ: ATRS) Is Up 4.18% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »
Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results 2022/02/17 13:30:00 GlobeNewswire
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens.
Antares resubmitted NDA for testosterone replacement therapy accepted by FDA 2022/02/03 14:26:40 Seeking Alpha
The FDA has accepted a New Drug Application for the oral testosterone replacement therapy Tlando from Antares Pharma.
Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference 2021/09/08 12:30:00 Intrado Digital Media
EWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, will participate and host investor meetings at the H.C. Wainwright 23 rd Annual Global Investment Conference being held on September 13-15, 2021.
Intramuscular Injector Market Analysis, Growth, Size and Forecast 2021 to 2027 | Antares Pharma, Endo International Plc, Bioject Medical Technologies 2021/09/03 10:05:46 OpenPR
The Global Intramuscular Injector Market analysis to 2027 is a specialized and in-depth study of the industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Intramuscular Injector market
Global Wegeners Granulomatosis/Granulomatosis with Polyangiitis Market Report Forecast to 2021-2027 |key players are Genentech, Inc., GlaxoSmithKline plc., Sonoma Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Antares Pharma, Medac Pharma, Inc., 2021/09/01 12:08:29 OpenPR
A newly published report on Wegeners Granulomatosis/Granulomatosis with Polyangiitis Market by Infinity Business Insights forecasts the market to grow at a robust rate. The ears, nose, throat, lungs, and kidneys can all be affected by granulomatosis with polyangiitis. It''s possible
Needle Free Drug Delivery Devices Market Report (2021-2028), Business Plan Strategy, New Solutions, Key Segments, Potential Targets and Recommendations | PenJet Corporation, Antares Pharma, Inc., Endo International plc., INJEX Pharma AG 2021/08/11 14:51:19 OpenPR
Needle-free drug delivery systems are an innovative way and method of delivery of drugs and other types of medicines. They can also be forms of transdermal patches, inhaling systems or even micro-needles that do not pierce the skin like a
Antares Pharma''s (ATRS) CEO Robert Apple on Q2 2021 Results - Earnings Call Transcript 2021/08/05 19:15:13 Seeking Alpha
Advanced Drug Delivery Market Huge Growth Potential in Future | Merck & Co, Antares Pharma, F. Hoffmann-La Roche, Novartis 2021/07/30 20:43:00 iCrowdNewswire
The Advanced Drug Delivery market research report added by Report Ocean, is an in-depth analysis of the latest developments, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with 
Antares Pharma to Report Second Quarter 2021 Financial and Operating Results 2021/07/28 12:30:00 Intrado Digital Media
EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced it will release its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the market opens.
Needle Free Injection Systems Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Antares Pharma, Valeritas, Bioject Medical Technologies, Endo International, Natio 2021/07/25 15:50:04 Jumbo News
This report studies the Needle Free Injection Systems Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Needle Free Injection Systems market segmented 
Autoinjectors Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Antares Pharma, Biogen Idec, Becton Dickinson, Mylan, Pfizer, Novartis International, Unilife, Yps 2021/07/24 22:18:27 Jumbo News
This report studies the Autoinjectors Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Autoinjectors market segmented by company, region, type and applications